Category Archives: Arkansas Stem Cells

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Frost & Sullivan

SINGAPORE, July 28, 2015 /PRNewswire/ --Faced with increasing challenges such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself. With few existing therapies capable of curing or significantly changing the course of a disease, healthcare providers are starting to look towards regenerative medicine as a viable alternative.

Regenerative medicine represents a new paradigm in human health with the potential to resolve unmet medical needs by addressing the underlying causes of diseases.

According to Dr. Jane Andrews, Senior Consultant, Healthcare & Life Sciences, Frost & Sullivan, regenerative medicine has the potential to cure diseases like we have never seen before. Because of this, the market, especially in the area of stem cell therapy, will continue to experience positive growth, boosted by support from other sectors.

"Regenerative Medicine initiatives are now attracting new public and private funding. Although Stem Cell Therapy will continue to be the largest market segment of Regenerative Medicine, cross segment therapies that combine the use of immunology, genetic and stem cell therapy are rapidly advancing," Andrews noted.

Regenerative medicine has also been an area of interest for major pharma companies, many of which have set up their own R & D units or have acquired stakes / invested in regenerative medicine companies. Major pharmaceutical companies which have done so include Pfizer, Johnson & Johnson and Teva Pharma.

Why Stem Cell Therapy?

In this space, cell therapy is the fastest growing segment of regenerative medicine and also the largest. Globally, the stem cell therapy market is expected to be worth US $40 billion by 2020 and US $180 billion by 2030.

Cell therapy involves the use of living cells to replace or augment damaged or diseased cells and tissues. It has been used for various conditions. The largest number of marketed cell therapy products is used for the treatment of notably non-healing wounds / skin (46%) and muscular-skeletal injuries (35%). This trend will change as more and stem cell therapy products for cancer and heart disease complete their clinical trials and are approved for market release.

Continued here:
Stem Cell Therapy to Redefine Regenerative Medicine, says ...

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, July 1, 2015 /PRNewswire/ -- Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today 404 companies plus partners developing 577 cancer stem cells and developmental pathways drugs in 2217 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 302 drugs. Cancer Stem Cells Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 324 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 318 out of the 320 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 60 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use? * Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.

Drug Pipeline Update at a Glance

Investigators Includes more than 404 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & Synonyms Lists commercial, generic and code names for drugs.

Developmental stage This Drug Pipeline Update contains 577 cancer stem cells and developmental pathways drugs in development, which have a total of 2217 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs Marketed# 41 Registered# 1 Pre-registration# 2 Phase III# 54 Phase II# 188 Phase I# 220 Preclinical# 431 No Data# 20 Suspended# 5 Ceased# 302

Read the original post:
Cancer Stem Cells Drug Pipeline Update 2015 - KAIT ...

This article was originally distributed via SproutNews. SproutNews, WorldNow and this Site make no warranties or representations in connection therewith.

BEVERLY HILLS, CA / ACCESSWIRE / June 12, 2015 / The Stem Cell Stock Review has updated coverage on the company and will be providing ongoing coverage. Roland Rick Perry, Editor of the Review stated Accurexas end goal is to provide a medical device that can save lives not by improving the therapeutics or drugs used to treat neurological disorders including brain tumors, but rather by improving the delivery method and effectiveness of currently approved drugs used to treat the disorders using a flexible delivery catheter. Adding, The device called Branchpoint is designed to permit Clinicians to tailor therapeutic delivery and give physicians more precise control of the volume of therapeutics delivered and ensure that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. We are excited to update coverage as they progress towards their filing a 510k submission with the FDA.

Accurexas Branchpoint microinjection brain catheter can be described as a quantum leap and game changing advancement in the technology of delivering drugs and therapeutics, directly to the brain over the common syringe (or cannula), as depicted in the report. The device was recently subject of a cover story in Molecular Therapy(R) (MT) magazine, the official journal of the American Society for Gene & Cell Therapy. The report can be viewed at both the Stem Cell and Bioteck Stock Review websites.

Stem Cell Stock Review Website: http://www.stemcellstockreview.com/research-reports.html

The Biotech Stock Review Website: http://www.thebiotechstockreview.com

About The Stem Cell Stock Review

The Stem Stock Review website provides individual news feeds for each company on the Watch List, enabling investors to easily follow the entire group with a single visit. Each Friday we issue a weekly head-line wrap up of stem cell industry news via our free newsletter. Also included are links to third party industry expert websites and leading news sources such as the Life Sciences Report, Edison Research, Futurity, the Timmerman Report, Fierce Biotech, BioMed Reports, Science Daily and research reports from a broad spectrum of Wall Street sources.

The Stem Cell Stock Review additionally has a Flipboard powered magazine which archives a collection of stem cell industry related articles from over 100 sources and can be found here: Stem Cell Stock Review Magazine: https://flipboard.com/@institution73s6/stem-cell-stock-review-8oe7m025y.

The Stem Cell Stock Review additionally has an online Internet TV channel called Biotech Exec TV, which hosts interviews with industry and Wall Street experts.

Biotech Exec TV: http://www.biotechexectv.com/

Read more:
Stem Cell Stock Review Updates Coverage On Accurexa - KATV ...

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, June 9, 2015 /PRNewswire/ -- About Stem Cell Banking Stem cells are the building blocks of the human body. They originate in the earliest stage of human development and can be found in the various stages of growth from birth till adulthood. When these undifferentiated biological cells divide, they can differentiate into specialized cells. A stem cell bank is a facility that stores stem cells for future use. Stem cell banking, one of the most promising markets in the field of life sciences, is the process of preserving stem cells at temperatures much below the freezing point. This technique is termed as cryopreservation. These cells can be used in the treatment of Parkinson's disease, diabetes, cancer, heart diseases, and others. Technavio's analysts forecast the stem cell banking market in India to grow at a CAGR of 37.85% over the period 2014-2019.

Covered in this Report This report covers the present scenario and the growth prospects of the stem cell banking market in India for the period 2015-2019. To calculate the market size, the report considers revenue generated by stem cell banking service providers. It presents the vendor landscape and corresponding detailed analysis of the top six vendors in the market. The report provides the segmentation of the market based on type of products, applications, and type of banks. Technavio's report, Stem Cell Banking Market in India 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years.

Key Vendors - CordLife Sciences India - Cryobanks International India - LifeCell International - Reliance Life Sciences - Stempeutics Research - Tran-Scell Biologics

Other Prominent Vendors - CordCare - Cryo Save India - Cryo Stemcell - International Stem Cell - Jeevan Blood Bank Research Centre - NovaCord - Reelabs - RMS Regrow - Stemade Biotech - StemCyte India Therapeutics - StemOne Biologicals - StemRx BioScience Solutions Key

Market Driver - Growing Potential for Umbilical Cord Cell Banks - For a full, detailed list, view our report Key

Market Challenge - Lack of Awareness - For a full, detailed list, view our report Key

Market Trend - Introduction of New Marketing Concepts - For a full, detailed list, view our report

Key Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors?

See the rest here:
Stem Cell Banking Market in India 2015-2019 - KAIT ...

Congregants attending the Applying 3D Models for Toxicological Research conference at the 14th Annual World Preclinical Congress (WPC), from June 10-12 in Boston, are anticipating an important new emphasis for tissue stem cell engineering of drug development platforms. At the Congress, tissue stem cell biotechnology start-up Asymmetrex will present its unique emphasis on what it calls the third dimension of time, which applies to its new technology for early detection of drug candidates that are likely to fail later because of poorly tolerated toxicity against adult tissue stem cells.

Boston, MA (PRWEB) May 28, 2015

In two different WPC forums, Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D., will present the companys unique approach to developing technologies for stem cell medicine. In a conference talk, he will describe Asymmetrexs innovation in integrating its proprietary stem cell culture designs with computer simulation to produce the first-ever technology for quantitative monitoring of adult tissue stem cell number and quality over time in culture. When leading an interactive breakout discussion group, Sherley will discuss with 3D tissue engineers how the tissue biology time principles that inspire Asymmetrexs technology might improve their engineered artificial tissue systems developed for use in pharmaceutical drug testing.

3D tissue engineering has the goal of developing facsimiles of normal or diseased human tissues that are more accessible and efficient for discovering and evaluating new therapeutic drugs. Human cell cultures in plastic petri dishes are called 2D systems, because they lack the higher dimension of cell architecture and connecting materials that constitute tissues in the body. In two weeks, at the 14th WPC, 3D tissue engineers interested in developing better tests for drug safety will convene to give special attention to new concepts and approaches for incorporating natural 3D properties into engineered 3D systems.

As disclosed by Sherley in a recent pre-congress interview, Asymmetrex is not a typical 3D tissue engineering company. Instead, its technology is based on specific attention to the dimension of time in 2D cultures containing human adult tissue stem cells. In collaboration with its partner, AlphaSTAR Corporation, Asymmetrex has integrated computer simulation with principles of the special manner in which tissue stem cells multiply over time in simple 2D cultures. Their resulting AlphaSTEM technology provides the ability to identify compounds that are tissue stem cell-toxic, for the first time, before employing animals in preclinical studies or human volunteers in Phase I clinical trials to evaluate drug safety.

In his conference talk, Sherley will describe the new AlphaSTEM technology and update progress on its technical and commercial development. Asymmetrex has studies under way to evaluate the predictive power of AlphaSTEM with panels of drugs of known toxicity against human adult tissue stem cells. Asymmetrex and AlphaSTAR have recently begun marketing their prototype technology to large and mid-range pharmaceutical companies for alpha testing. About 10% of new drug candidates are estimated to fail in preclinical animal testing or clinical trials because of adult tissue stem cell toxicity. By detecting these future failures earlier in the pipeline, AlphaSTEM technology is projected to accelerate drug development, reduce its cost, and improve drug safety. With widespread use, AlphaSTEM could reduce U.S. drug development costs by $4-5 billion each year.

In his interactive breakout presentation, Sherley plans to discuss how the same third dimension of time principles are important in traditional 3D tissue engineering towards building drug testing systems that are more faithful to the properties of tissues in the body. In many organs and tissues in the body, cell multiplication and movement occur continuously. However, although current tissue engineering strategies are well-focused on mimicking physical 3D features, they largely overlook crucial features related to time like tissue stem cell dynamics. By learning about the essential role of tissue stem cell time in Asymmetrexs 2D AlphaSTEM technology, Sherley hopes that 3D tissue engineers will be inspired to consider its value in their efforts to engineer better 3D tissue systems for drug evaluations.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/05/prweb12751696.htm

Read this article:
Asymmetrex Will Discuss the Importance of Adult Tissue ...

by David M. Panchision*

Diseases of the nervous system, including congenital disorders, cancers, and degenerative diseases, affect millions of people of all ages. Congenital disorders occur when the brain or spinal cord does not form correctly during development. Cancers of the nervous system result from the uncontrolled spread of aberrant cells. Degenerative diseases occur when the nervous system loses functioning of nerve cells. Most of the advances in stem cell research have been directed at treating degenerative diseases. While many treatments aim to limit the damage of these diseases, in some cases scientists believe that damage can be reversed by replacing lost cells with new ones derived from cells that can mature into nerve cells, called neural stem cells. Research that uses stem cells to treat nervous system disorders remains an area of great promise and challenge to demonstrate that cell-replacement therapy can restore lost function.

The nervous system is a complex organ made up of nerve cells (also called neurons) and glial cells, which surround and support neurons (see Figure 3.1). Neurons send signals that affect numerous functions including thought processes and movement. One type of glial cell, the oligodendrocyte, acts to speed up the signals of neurons that extend over long distances, such as in the spinal cord. The loss of any of these cell types may have catastrophic results on brain function.

Although reports dating back as early as the 1960s pointed towards the possibility that new nerve cells are formed in adult mammalian brains, this knowledge was not applied in the context of curing devastating brain diseases until the 1990s. While earlier medical research focused on limiting damage once it had occurred, in recent years researchers have been working hard to find out if the cells that can give rise to new neurons can be coaxed to restore brain function. New neurons in the adult brain arise from slowly-dividing cells that appear to be the remnants of stem cells that existed during fetal brain development. Since some of these adult cells still retain the ability to generate both neurons and glia, they are referred to as adult neural stem cells.

These findings are exciting because they suggest that the brain may contain a built-in mechanism to repair itself. Unfortunately, these new neurons are only generated in a few sites in the brain and turn into only a few specialized types of nerve cells. Although there are many different neuronal cell types in the brain, we now know that these new neurons can quot;plug inquot; correctly to assist brain function.1 The discovery of these cells has spurred further research into the characteristics of neural stem cells from the fetus and the adult, mostly using rodents and primates as model species. The hope is that these cells may be able to replenish those that are functionally lost in human degenerative diseases such as Parkinson's Disease, Huntington's Disease, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), as well as from brain and spinal cord injuries that result from stroke or trauma.

Scientists are applying these new stem cell discoveries in two ways in their experiments. First, they are using current knowledge of normal brain development to modulate stem cells that are harvested and grown in culture. Researchers can then transplant these cultured cells into the brain of an animal model and allow the brain's own signals to differentiate the stem cells into neurons or glia. Alternatively, the stem cells can be induced to differentiate into neurons and glia while in the culture dish, before being transplanted into the brain. Much progress has been made the last several years with human embryonic stem (ES) cells that can differentiate into all cell types in the body. While ES cells can be maintained in culture for relatively long periods of time without differentiating, they usually must be coaxed through many more steps of differentiation to produce the desired cell types. Recent studies, however, suggest that ES cells may differentiate into neurons in a more straightforward manner than may other cell types.

Figure 3.1. The Neuron When sufficient neurotransmitters cross synapses and bind receptors on the neuronal cell body and dendrites, the neuron sends an electrical signal down its axon to synaptic terminals, which in turn release neurotransmitters into the synapse that affects the following neuron. The brain neurons that die in Parkinson's Disease release the transmitter dopamine. Oligodendrocytes supply the axon with an insulating myelin sheath.

2001 Terese Winslow

Second, scientists are identifying growth (trophic) factors that are normally produced and used by the developing and adult brain. They are using these factors to minimize damage to the brain and to activate the patient's own stem cells to repair damage that has occurred. Each of these strategies is being aggressively pursued to identify the most effective treatments for degenerative diseases. Most of these studies have been carried out initially with animal stem cells and recipients to determine their likelihood of success. Still, much more research is necessary to develop stem cell therapies that will be useful for treating brain and spinal cord disease in the same way that hematopoietic stem cell therapies are routinely used for immune system replacement (see Chapter 2).

The majority of stem cell studies of neurological disease have used rats and mice, since these models are convenient to use and are well-characterized biologically. If preliminary studies with rodent stem cells are successful, scientists will attempt to transplant human stem cells into rodents. Studies may then be carried out in primates (e.g., monkeys) to offer insight into how humans might respond to neurological treatment. Human studies are rarely undertaken until these other experiments have shown promising results. While human transplant studies have been carried out for decades in the case of Parkinson's disease, animal research continues to provide improved strategies to generate an abundant supply of transplantable cells.

Originally posted here:
3. Repairing the Nervous System with Stem Cells [Stem Cell ...

Mesenchymal stem cells (MSCs) are pluripotent cells found in multiple human adult tissues including bone marrow, synovial tissues, and adipose tissues. Since they are derived from the mesoderm, they have been shown to differentiate into bone, cartilage, muscle, and adipose tissue.[1] MSCs from embryonic sources have shown promise scientifically while creating significant controversy. As a result, many researchers have focused on adult stem cells [1], or stem cells isolated from adult humans that can be transplanted into damaged tissue.

Because of their multi-potent capabilities, mesenchymal stem cell (MSC) lineages have been used successfully in animal models to regenerate articular cartilage and in human models to regenerate bone.[2][3][4] Recent research demonstrates that articular cartilage may be able to be repaired via percutaneous introduction of mesenchymal stem cells (MSCs).[5]

Research into MSCs has exploded in recent years. As an example, a PubMed search for the year 1999 reveals about 90 papers published under the MESH heading of Mesenchymal Stem Cells, the same search ran for the year 2007 reveals more than 4,000 entries. The most commonly used source of MSCs is bone marrow aspirate. Most of the adult bone marrow consists of blood cells in various stages of differentiation.[6] These marrow components can be divided into plasma, red blood cells, platelets, and nucleated cells. The adult stem cell fraction is present in the nucleated cells of the marrow. Most of these cells are CD34+ heme progenitors (destined to differentiate into blood components), while very few are actually MSCs capable of differentiating into bone, cartilage, or muscle. As a result, that leaves the very small number of MSCs in the marrow as cells capable of differentiating into tissues of interest to joint preservation.[7] Of note, this may be one of the reasons that commercially available centrifuge systems that concentrate marrow nucleated cells have not shown as much promise in animal research for cartilage repair as have approaches where MSCs are expanded in culture to greater numbers.

Marrow nucleated cells are used every day in regenerative orthopedics. The knee microfracture surgery technique popularized by Steadman[8] relies on the release of these cells into a cartilage lesion to initiate fibrocartilage repair in osteochondral defects.[9] In addition, this cell population has also been shown to assist in the repair of non-union fractures.[10] For this application, bed side centrifugation is commonly used. Again, these techniques produce a very dilute MSC population, usually a yield of 1 in 10,000-1,000,000 of the nucleated cells.[11] Despite this low number of MSCs, isolated bone marrow nucleated cells implanted into degenerated human peripheral joints have shown some promise for joint repair.[12] As the number of MSCs that can be isolated from bone marrow is fairly limited, most research in cartilage regeneration has focused on the use of culture expanded cells.[13][14] This method can expand cell numbers by 100-10,000 fold over several weeks. Once these MSCs are ready for re-implanation, they are usually transferred with growth factors to allow for continued cell growth and engraftment to the damaged tissue. At some point, a signal is introduced (either in culture or after transplant to the damaged tissue) for the cells to differentiate into the end tissue (in this discussion, cartilage).

Until recently, the use of cultured mesenchymal stem cells to regenerate cartilage has been primarily in research with animal models. There are now, however, two published case reports of the above technique being used to successfully regenerate articular and meniscus cartilage in human knees.[15][16] This technique has yet to be shown effective in a study involving a larger group of patients, however the same team of researchers have published a large safety study (n=227) showing fewer complications than would normally be associated with surgical procedures. [17]

Another team used a similar technique for cell extraction and ex vivo expansion but cells were embedded within a collagen gel before being surgically re-implanted. They reported a case study in which a full-thickness defect in the articular cartilage of a human knee was successfully repaired.[18]

While the use of cultured mesenchymal stem cells has shown promising results, a more recent study using uncultured MSCs has resulted in full thickness, histologically confirmed hyaline cartilage regrowth. Dr. Khay-Yong Saw and his team evaluated the quality of the repair knee cartilage after arthroscopic microdrilling (also microfracture) surgery followed by post-operative injections of autologous peripheral blood progenitor cells (PBPC) in combination with hyaluronic acid(HA).[19] PBPCs are a blood product containing MSCs, which is obtained by mobilizing stem cells into the peripheral blood. In February 2011, the team published the results of a 5 patient case series. All five patients showed evidence of hyaline cartilage regeneration at second-look arthroscopy and subsequent biopsy, including 2 patients with full thickness bipolar or kissing lesions. The authors propose that the microdrilling surgery creates a blood clot scaffold on which injected PBPCs can be recruited and enhance chondrogenesis at the site of the contained lesion. They explain that the significance of this cartilage regeneration protocol is that it is successful in patients with historically difficult-to-treat grade IV bipolar or bone-on-bone osteochondral lesions.

Dr. Saw and his team are currently conducting a larger randomized trial and working towards beginning a multicenter study. The work of the Malaysian research team is gaining international attention.[20]

See original here:
Stem cell transplantation for articular cartilage repair ...

Tuesday, the Nebraska Medical Center will once again be in the national spotlight, featured on the reality television show 19 Kids and Counting.

The show focuses on the lives of Jim Bob and Michelle Duggar and their 19 biological children. Recently, the program has also included the Dillard family, when Derick Dillard married one of the Duggar children, Jill. His mother, Cathy Dillard Byrum, has battled Non-Hodgkins Lymphoma, a fight that brought her to Nebraska Medicine last fall.

Dillard Byrum recently spoke to KETVs Brandi Petersen via Skype from her home in Arkansas.

I feel wonderful, Im back to my old self, Dillard Byrum said. She added that through her faith, she was always confident she would beat the cancer, despite a grim diagnosis. When doctors first diagnosed the cancer after a node biopsy, they determined it was stage four and had spread to Dillard Byrums spleen, liver and bone marrow.

I learned that he had not had anyone survive that at the time, said Dillard Byrum. I shall not die, but live, and declare the works of the Lord. I knew I wasnt going to die, but I didnt know how close I would come.

Dillard Byrum describes a grueling chemotherapy regimen, and a fall in her bathroom in the weeks leading up to her sons wedding, shown on 19 Kids And Counting. Doctors later told her with her weakened body from the chemo, she could have bled out in her bathroom from that fall.

About a week before the wedding, and I think you saw this on the show, they air-flighted me, thinking they were going to have to do brain surgery a week before the wedding, said Dillard Byrum. And my doctor told me later he didnt think Id survive the helicopter flight to the other hospital.

She did, and by the end of the summer tests showed the chemotherapy had been successful. Dillard Byrums next step was a stem cell transplant to try and prevent the high-risk cancer from returning. Dillard Byrums doctor told her he wanted her to go to Omaha.

I thought, why Omaha? said Dillard Byrum. I learned, especially over the course of being there, thats the go-to place for this kind of lymphoma.

Dr. Julie Vose, an oncologist and hematologist with Nebraska Medicine, became Dillard Byrums doctor.

Read more:
Reality TV show, cancer patient come to Omaha for transplant

Parents-to-be Jill and Derick Dillard were sad his cancer survivor mother Cathy wouldnt be with them as they learned their babys gender on Tuesdays 19 Kids and Counting.

Cathy was getting ready to Omaha, Nebraska for treatment to prevent recurrence of her cancer and Jill made a cheesecake and snack care package for her mother-in-law.

As Jill recalled, Cathys battle with cancer dovetailed with the couples had happened when the couple got married last year, and they were overjoyed she was able to make it to the wedding.

PHOTOS: Jill Duggar and Derick Dillards Wedding Day Revealed!

On Tuesdays episode, Cathy chowed down on the food theyd brought and told Jill and Derick, Ill pack on more pounds in the next four days than I have in the last three months.

Jill told the cameras, It is hard for me to see Dericks mom go through these health problems, and yet I know shes very strong and has lots of people praying for her.

Cathy said she would get stem cell transplant of her own stem cells during the therapy.

PHOTOS: Beautiful Jill Duggar Proudly Bares Baby Bump In Blue In NYC

My mom will be going for treatment, doing some procedures to keep the chance of her cancer recurring to a minimum, Derick said. He added that looking forward to her first grandchild definitely gives her some incentive to get better.

Dillard said he and Jill would find out the gender of their baby in their Arkansas hometown while Cathy was in Omaha.

See the rest here:
Derick Dillards Mom Cathy Gets Treatment To Keep Cancer At Bay, While Jill Suffers Morning Sickness

Maryann DePietro

MaryAnn DePietro has been a professional journalist since 2000, specializing in health, fitness and medical articles. She is also a certified respiratory therapist. Her work has appeared on websites such as eHow and ModernMom and in publications including the Sacramento Bee, Press Tribune and Succeed. DePietro holds a Bachelor of Science in rehabilitation from Penn State University and a degree in respiratory therapy.

There are different types of bone marrow transplants, including an allogeneic and an autologous transplant. In allogeneic bone marrow transplants, stem cells come from a donor. According to Memorial Sloan-Kettering Cancer Center, during an autologous transplant, the patient's own stem cells are used. Although an autologous stem cell transplant can involve months of recovery and may have side effects, it can be lifesaving in certain situations.

Bone marrow transplants, sometimes called stem cell transplants, can have trully remarkable results for patients with many different kinds of cancer. Non...

What Are the Side Effects of Stem Cell Transplantation? X. ... Autologous Stem Cell Transplant. There are different types of bone marrow...

Autologous Stem Cell Treatment. Autologous stem cell treatment involves removing stem cells from a patient's own bone marrow, storing them and transplanting...

Doctors resort to stem cell and bone marrow transplants to battle a difficult disease like cancer. ... Autologous Stem Cell Transplant; Bone...

Stem-Cell Transplant Vs. Bone-Marrow Transplant. ... Autologous Stem Cell Transplant. There are different types of bone marrow transplants, ...

During the recovery phase ... Going through a stem cell transplant can be a traumatic event, as the procedure can require a...

Thyromine Side Effects. ... hence damaging its cells and disrupting ... The ginger supplement is an underground stem (a rhizome) ...

Read this article:
Autologous Stem Cell Transplant | eHow